 | The Drug Delivery Partnering Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology or drug delivery-enabled product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. |
|
 | The Partnering Agreements in Diagnostics report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies. * Comprehensive directory of diagnostic deals since 2003 * Diagnostic contract documents * Diagnostic agreement terms * Diagnostic agreement structure * Top diagnostic deals by value * Most active diagnostic dealmakers |
|
 | The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered into by the worlds leading biopharma companies. |
|
 | The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. |
|
 | The Royalty Financing Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals. * Comprehensive directory of royalty financing deals since 2003 * Royalty financing contract documents * Royalty financing agreement terms * Royalty financing agreement structure * Top royalty financing deals by value * Most active Royalty financing dealmakers |
|
 | The Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter asset purchase deals. * Product purchase contract documents * Asset purchase contract documents * Product and asset purchase agreement terms * Product and asset purchase agreement structure * Top Product and asset purchase deals by value * Most active Product and asset purchase dealmakers |
|
 | The Discovery Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies |
|
 | The Partnering with Bigpharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. |
|
 | The Pre-clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the pre-clinical stage partnering agreements entered into by the worlds leading biopharma companies |
|
 | The Clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the clinical stage partnering agreements entered into by the worlds leading biopharma companies. |
|
 | The Manufacturing and Supply Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies.The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.This report contains over 1000 links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. |
|
 | The Distribution Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.The report provides a detailed understand and analysis of how and why companies enter distribution deals.The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. |
|
 | The Co-promotion and Co-marketing Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace. |
|
 | The Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies. |
|
 | The Bigpharma Partnering Agreements provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.The Bigpharma Partnering Agreements provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.Understanding the flexibility of a prospective partner’s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. |
|
 | CurrentPartnering’s Practical Guide to Finding Partners in Pharma & Biotech provides a comprehensive overview of all the steps required to identify and secure partnering either for an in-licensing or out-licensing activity. |
|
 | The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.The combined Bigpharma Dealmaking and Agreements Handbook 2007 provides the entire content of both reports at a great discounted price.Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. |
|
 | SummaryThe Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.DescriptionBigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.Understanding the flexibility of a prospective partner’s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners. |
|
 | SummaryThe Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.Report descriptionThe Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner. Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities.The main body of the report is provided in chapter 7 and 8. Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years. Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which can be obtained from CurrentPartnering, either individually or as part of a contract set. See each company profile for further details.Formats available: PDF |
|
